Science-Backed Skincare Brand Epicutis Secures Investment

Skincare brand Epicutis secures strategic growth investment from GroundForce Capital to expand across medispas, clinics, and spas.

What happened

Epicutis has secured a $25 million minority investment from GroundForce Capital. The funding will support the US skincare brand’s plans to expand its presence across dermatology clinics, medispas, and luxury spas, while also going towards product development and wider brand awareness.

Why it matters

Founded by Maxwell Stock in partnership with Princeton University biophysicist Dr Jeffry Stock, Epicutis brings a research-heavy approach to product development. Its formulas are built around a small group of proprietary, patented molecules developed in-house, including TSC, HYVIA, and DSD, rather than long ingredient lists or trend-led actives. Product development is led by Masanori Tamura, who previously spent more than a decade at Rohto Pharmaceuticals and worked on Japanese skincare brand Hada Labo.

“Epicutis exists because we believed skincare deserved real science — actives discovered in the lab, published in the literature, and trusted by practitioners before they ever reach a shelf,” said Maxwell Stock. “GroundForce understood that discipline from our very first conversation. This partnership lets us move faster on everything that matters: the discovery pipeline behind the brand, the professional channel we intend to lead, and the standard of proof we hold ourselves to.”

GroundForce Capital already backs consumer brands including Liquid Death, Bobbie, OWYN, Vive Organic, and Thistle. As part of the deal, the investment firm will also join Epicutis’s board.

This news brief is based on reporting published by Beauty News Daily on 2026-08-20. The original report is linked below.